Delmadinone acetate (DMA) was first described in the scientific literature in 1959 and has been marketed since at least 1972.[1][8][9] By that time, it was marketed inEurope and theUnited Kingdom under the brand namesTardak andZenadrex.[9] It was also under development for use in theUnited States, but it does not appear to have been marketed there.[9]
Delmadinone acetate is thegeneric name of the drug and itsUSANTooltip United States Adopted Name andBANMTooltip British Approved Name.[1][2][3][4]Delmadinone is theINNTooltip International Nonproprietary Name andBANTooltip British Approved Name of the unesterified freealcohol form.[1][2][3][4]
DMA is most commonly marketed under the brand nameTardak, but has also been sold under several other brand names, includingDelmate,Estrex,Tardastren,Tardastrex,Vetadinon, andZenadrex.[1][2][4]
^Court EA, Watson AD, Church DB, Emslie DR (August 1998). "Effects of delmadinone acetate on pituitary-adrenal function, glucose tolerance and growth hormone in male dogs".Australian Veterinary Journal.76 (8):555–560.doi:10.1111/j.1751-0813.1998.tb10216.x.PMID9741725.
^McRobb L, Handelsman DJ, Kazlauskas R, Wilkinson S, McLeod MD, Heather AK (May 2008). "Structure-activity relationships of synthetic progestins in a yeast-based in vitro androgen bioassay".The Journal of Steroid Biochemistry and Molecular Biology.110 (1–2):39–47.doi:10.1016/j.jsbmb.2007.10.008.PMID18395441.S2CID5612000.
^Ringold HJ, Batres E, Bowers A, Edwards J, Zderic J (1959). "Steroids. CXXVII. 16-Halo Progestational Agents".Journal of the American Chemical Society.81 (13):3485–3486.doi:10.1021/ja01522a090.ISSN0002-7863.
^abcModern Veterinary Practice. Vol. 53. 1972. p. 46.John T. Bryans, University of Kentucky, Lexington. Thoroughbred Record 194(22): 1634–1636, 1971. In the clinical review entitled "Antiandrogen Treatment of Prostate Disorders" (MVP Oct, p. 46) the product should have been identified as delta-chlor-madinone acetate (delta-CAP), rather than as CAP. This compound, also known as delmadinone acetate, has unique properties and is marketed in Europe and the UK as Tardak and Zenadrex; it is presently subject to clinical investigation in the US for FDA approval.
